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A bs tr ac t
Background
Cellulitis of the leg is a common bacterial infection of the skin and underlying tissue. 
We compared prophylactic low-dose penicillin with placebo for the prevention of 
recurrent cellulitis.
Methods
We conducted a double-blind, randomized, controlled trial involving patients with 
two or more episodes of cellulitis of the leg who were recruited in 28 hospitals in 
the United Kingdom and Ireland. Randomization was performed according to a 
computer-generated code, and study medications (penicillin [250 mg twice a day] or 
placebo for 12 months) were dispensed by a central pharmacy. The primary outcome 
was the time to a first recurrence. Participants were followed for up to 3 years. 
Because the risk of recurrence was not constant over the 3-year period, the primary 
hypothesis was tested during prophylaxis only.
Results
A total of 274 patients were recruited. Baseline characteristics were similar in the 
two groups. The median time to a first recurrence of cellulitis was 626 days in the 
penicillin group and 532 days in the placebo group. During the prophylaxis phase, 
30 of 136 participants in the penicillin group (22%) had a recurrence, as compared 
with 51 of 138 participants in the placebo group (37%) (hazard ratio, 0.55; 95% 
confidence interval [CI], 0.35 to 0.86; P = 0.01), yielding a number needed to treat to 
prevent one recurrent cellulitis episode of 5 (95% CI, 4 to 9). During the no-intervention 
follow-up period, there was no difference between groups in the rate of a first recur-
rence (27% in both groups). Overall, participants in the penicillin group had fewer 
repeat episodes than those in the placebo group (119 vs. 164, P = 0.02 for trend). 
There was no significant between-group difference in the number of participants 
with adverse events (37 in the penicillin group and 48 in the placebo group, P = 0.50).
Conclusions
In patients with recurrent cellulitis of the leg, penicillin was effective in preventing 
subsequent attacks during prophylaxis, but the protective effect diminished pro-
gressively once drug therapy was stopped. (Funded by Action Medical Research; 
PATCH I Controlled-Trials.com number, ISRCTN34716921.)
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Cellulitis of the leg is a common in-fection of the skin and subcutaneous tis-sue.1,2 Most infections that affect intact 
skin are thought to be due to streptococci,3,4 al-
though other organisms may be responsible if 
the integrity of the skin is compromised. Each 
recurrent episode of cellulitis results in further 
damage to the lymphatic system5,6 and is associ-
ated with additional morbidity and health care 
costs.7 Current guidelines for the prevention of 
cellulitis are consensus-based and recommend pro-
phylactic antibiotic therapy for recurrent disease.8,9 
Three small, randomized, controlled trials have 
suggested a possible benefit of prophylactic anti-
biotics in patients with recurrent cellulitis,10-12 but 
clinical opinion is mixed.
We conducted the Prophylactic Antibiotics for 
the Treatment of Cellulitis at Home I (PATCH I) 
trial to examine the effectiveness of a 12-month 
course of low-dose penicillin for the prevention 
of cellulitis of the leg in persons with recurrent 
disease. This study builds on data from a previ-
ous study of 6 months of penicillin prophylaxis, 
primarily in patients with a first episode of cel-
lulitis of the leg.2
Me thods
Trial Design and Oversight
This double-blind, randomized, controlled trial 
compared 12 months of prophylactic phenoxy-
methylpenicillin (penicillin) with placebo in pa-
tients with recurrent cellulitis. Participants were 
monitored for up to 36 months (minimum, 18). 
Changes to the trial protocol after the start of 
recruitment included the following: the number 
of repeat episodes of cellulitis was added as a 
secondary outcome, since this outcome had been 
erroneously omitted; and to boost recruitment, 
the window between the end of the index episode 
and recruitment was extended from 3 to 6 months 
and potential participants were sought through 
direct advertising to the public. For full details of 
the trial design, see the protocol, available with the 
full text of this article at NEJM.org.
Appropriate national ethics and regulatory ap-
provals were obtained; all participants gave written 
informed consent. The Medical Research Council 
Clinical Trials Unit provided input into the design 
and conduct of the trial and performed the sta-
tistical analysis. All the authors vouch for the 
completeness and accuracy of the data presented 
and for the fidelity of the study to the protocol. 
There was no commercial support for this study.
Participants
Recruitment took place at 28 hospitals in the 
United Kingdom and Ireland between July 2006 
and January 2010 (date of last follow-up contact, 
July 2011). Participants were identified in a hos-
pital setting or through direct advertising.
Patients who had had a recurrent episode of 
leg cellulitis within the previous 24 weeks were 
eligible for inclusion. Patients were considered to 
have recurrent cellulitis if they had had at least 
two episodes of cellulitis of the leg within the 
previous 3 years (as assessed by the recruiting 
dermatologist on the basis of a history taking 
and clinical examination). If a patient was not 
assessed by a dermatologist during the acute epi-
sode, the diagnosis was confirmed on the basis 
of the patient’s medical records at the recruit-
ing hospital in combination with an interview 
with the patient. The following were required: 
local warmth, tenderness, or acute pain; unilat-
eral erythema or bilateral erythema, with a tem-
poral association between symptoms and the 
more severely affected leg; and unilateral edema. 
If there was doubt about the certainty of the 
diagnosis, the patient was excluded.
Other exclusion criteria were the use of anti-
biotics for the prevention of cellulitis in the pre-
ceding 6 months; allergy to penicillin; previous 
leg ulceration, surgery, or penetrating trauma; an 
unwillingness of the recruiting clinician to ran-
domly assign the patient for medical reasons; an 
age of less than 16 years; an inability to give in-
formed consent; and current participation in an-
other clinical trial.
Interventions
Participants received low-dose oral penicillin 
(250 mg) or placebo (consisting of calcium phos-
phate, starch, cellulose, and magnesium stearate) 
twice daily after completion of treatment for the 
index episode of cellulitis. Normal clinical practice 
was observed for the treatment of predisposing 
factors such as tinea pedis.
Adherence to trial medication was assessed by 
means of self-reported pill counts collected during 
follow-up telephone calls. These data were cate-
gorized as no pills taken, hardly any taken (1 to 
24% of prescribed doses), some taken (25 to 49%), 
most taken (50 to 74%), or all taken (75 to 100%).
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Randomization, Blinding, and Follow-up
The coordinating center randomly assigned the 
participants with the use of the Nottingham 
Clinical Trials Unit (NCTU) Web-based random-
ization service. Randomization was stratified ac-
cording to the presence or absence of preexisting 
edema and of ulceration associated with the cel-
lulitis. The computer-generated randomization list 
was produced before the start of recruitment, with 
the use of randomly varying block sizes, and was 
held by the NCTU. Treatment assignments were 
sent electronically to the pharmacy department at 
Queen’s Medical Centre, Nottingham, where the 
medications were dispensed with the use of iden-
tical labeling and packaging and were mailed to 
the participants’ homes.
Participants and all members of the study 
team were unaware of the treatment assignments 
throughout the trial, and the analysis was per-
formed before the breaking of the randomiza-
tion code. Although the study medications were 
packaged in an identical way and the placebo 
tablets were the same size and shape as the 
penicillin tablets, the tablets were not identical 
owing to the cost implications of overencapsula-
tion (the placebo tablets were unmarked, and the 
penicillin tablets were marked). The risk of un-
blinding by direct comparison of active and pla-
cebo tablets was low, because participants were 
recruited from a wide geographic area, with lit-
tle or no contact with each other. In addition, the 
primary outcome was confirmed on the basis of 
medical records kept by general practitioners in 
order to reduce potential detection bias from un-
blinding.
Follow-up telephone calls from the coordinat-
ing center were conducted at 3-month intervals 
during the prophylaxis phase (0 to 12 months) and 
at 6-month intervals during the follow-up phase 
(13 to 36 months). Participants recorded adverse 
events and the use of health services in a diary.
Outcomes
The primary outcome measure was the time from 
randomization to the next medically confirmed 
episode of cellulitis. The episode was considered 
to have started on the first day of symptoms re-
ported by the participant. Episodes reported by 
the participant and resulting in antibiotic treat-
ment but not confirmed by a medical profession-
al were documented as self-confirmed cases and 
included in the sensitivity analysis.
Secondary outcome measures were the pro-
portions of participants with a repeat episode of 
cellulitis during the prophylaxis phase and dur-
ing the follow-up phase, the number of repeat 
episodes of cellulitis, the proportions of partici-
pants with new edema or ulceration during the 
prophylaxis phase and during the follow-up phase, 
the number of nights in the hospital for cellulitis, 
the number of adverse drug reactions or adverse 
events of interest (death, nausea, diarrhea, thrush, 
rash, severe skin reactions, sepsis, and renal fail-
ure), and cost-effectiveness. In addition, predictors 
of response were included as secondary outcomes 
in order to explore the effect of known risk fac-
tors on prediction of the efficacy of prophylaxis.
Statistical Analysis
We assumed a 50% reduction in the recurrence rate 
with penicillin as compared with placebo on the 
basis of a log-rank test for time-to-event data, with 
80% power at a two-sided significance level of 5% 
and an expected 20% rate of loss to follow-up. 
Previous studies have shown possible recurrence 
rates of 30 to 50%, depending on the population 
and the duration of follow-up.13,14 For the relapse 
rate in the placebo group, we used a conservative 
estimate of 35% over a period of 3 years. These 
calculations resulted in a sample size of 260 par-
ticipants.
All analyses were prespecified in the statisti-
cal analysis plan. Analysis of the primary outcome 
included all randomly assigned participants, with 
no exclusions (intention-to-treat population). The 
time to recurrence was analyzed with the use of a 
Cox proportional-hazards model, and participants 
with limited follow-up data were included in the 
analysis but with data censored accordingly. The 
primary analysis was unadjusted, but the results 
of an analysis adjusted for stratification factors 
are also presented. Because the assumption of a 
constant hazard over time was not met (P = 0.05), 
it was necessary to limit the piecewise Cox pro-
portional-hazards model to the 12-month prophy-
laxis period for the primary analysis.15 The end 
of the prophylaxis period was prespecified in the 
statistical analysis plan as being a logical cutoff 
point for such a piecewise model. Results of an 
analysis of the 2-year and 3-year follow-up data are 
presented but should be considered supportive of 
the primary analysis. In addition, five sensitivity 
analyses of the primary outcome were conducted: 
episodes of self-confirmed cellulitis recurrences 
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were included; participants who did not start the 
study medication or who reported a relapse within 
4 weeks after randomization were excluded be-
cause incomplete treatment of the index episode 
was likely; participants who had received treat-
ment for the index episode more than 12 weeks 
before randomization were excluded (a protocol 
change); patients with recurrences that were 
preceded by ulceration or trauma (in line with 
inclusion criteria) were excluded; and patients 
were stratified according to recruitment source 
(hospital or community).
For the secondary outcomes, differences in pro-
portions of participants were compared with the 
use of the chi-square test, and differences in the 
proportion of participants reporting multiple epi-
sodes were compared with the use of the Mann–
Whitney rank-sum test. A logistic-regression mod-
el was developed to explore factors associated 
with the failure of prophylaxis (defined as at 
least one confirmed episode of cellulitis during 
the prophylaxis phase). All baseline factors list-
ed in Table 1 were included in the model, plus 
the interval between the index episode of cellu-
litis and randomization.
Undiscounted costs of care were estimated by 
applying published national reference costs16-18 to 
the use of resources. Confidence intervals were 
estimated with the use of bootstrapping meth-
ods, with 10,000 replications for each item.19 Two 
cost estimates are provided: the cost of U.K. Na-
tional Health Service (NHS) resources alone and 
the overall societal cost, which included the cost 
of time lost from work or daily activities. All 
statistical analyses were conducted with the use 
of Stata software, version 11.2 (StataCorp).
R esult s
Participants
Recruitment took place from July 2006 through 
January 2010. Of 533 patients screened, 274 were 
eligible and gave written informed consent; 136 
were assigned to the penicillin group, and 138 to 
the placebo group (Fig. 1). Of these patients, 15 
(5%) withdrew consent or were lost to follow-up 
and 11 (4%) died. A total of 206 patients (75%) 
were recruited in secondary care. The baseline 
characteristics of the participants were well bal-
anced between the groups (Table 1).
A total of 247 patients (90%) underwent at least 
18 months of follow-up (median, 25). Slower-than-
anticipated recruitment meant that follow-up was 
limited for those recruited toward the end of the 
trial. A total of 214 participants (78%) reported 
taking at least 75% of the study tablets; the pro-
portion of patients who reported taking at least 
75% of the tablets was similar in the two groups 
(79% in the penicillin group and 78% in the 
placebo group).
Primary Outcome
The median time to the first confirmed recurrence 
of cellulitis was 626 days in the penicillin group 
and 532 days in the placebo group. During the 
prophylaxis phase, 30 of 136 participants who 
received penicillin (22%) had a recurrence, as com-
pared with 51 of 138 participants who received 
placebo (37%). Results from the Cox proportional-
hazards model are summarized in Table 2.
During the prophylaxis phase, participants in 
the penicillin group had a 45% reduction in the 
risk of a repeat episode of cellulitis, as compared 
with those in the placebo group (hazard ratio, 
0.55; 95% confidence interval [CI], 0.35 to 0.86; 
P = 0.01). This is equivalent to an absolute differ-
ence in event rates of 15 percentage points and a 
number needed to treat to prevent one repeat 
episode of 5 (95% CI, 4 to 9). However, this sig-
nificant effect was not sustained after prophy-
laxis ceased (Table 2 and Fig. 2). The results of 
all sensitivity analyses were consistent with the 
primary result.
Secondary Outcomes
The proportions of patients with a repeat episode 
of cellulitis during the prophylaxis phase and dur-
ing the follow-up phase are shown in Table 2. Of 
the 129 participants with at least one confirmed 
repeat episode, 50 (39%) had one repeat episode, 
38 (29%) had two, 20 (16%) had three, and 21 (16%) 
had four or more. Overall, participants in the 
penicillin group had fewer repeat episodes than 
those in the placebo group (119 vs. 164, P = 0.02 
for trend). During the prophylaxis phase, there 
were 76 repeat episodes in the penicillin group, as 
compared with 122 in the placebo group (P = 0.03). 
During the follow-up phase, there were 43 and 42 
repeat episodes in the penicillin and placebo 
groups, respectively (P = 0.88).
A total of 89 participants (32%) had no edema 
or ulceration at baseline, but 54 had these symp-
toms during the trial. There were no significant 
between-group differences in the development of 
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edema or ulceration during either the prophylaxis 
phase (40% in the penicillin group and 48% in the 
placebo group, P = 0.46) or the follow-up phase 
(40% and 45%, respectively; P = 0.60).
Safety
During the prophylaxis phase, one or more ad-
verse events of prespecified interest occurred in 
85 participants (37 in the penicillin group and 48 
in the placebo group, P = 0.50) (see Table S1 in the 
Supplementary Appendix, available at NEJM.org). 
Eleven participants died during the trial (8 in the 
penicillin group and 3 in the placebo group, 
P = 0.14); none of the deaths were considered to 
be related to the study drugs (Table S1 in the Sup-
plementary Appendix).
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic
Penicillin
(N = 136)
Placebo
(N = 138)
Preexisting leg edema or ulceration associated with cellulitis —  
no. of patients (%)
Neither 45 (33) 44 (32)
Edema 81 (60) 82 (59)
Ulceration 1 (1) 2 (1)
Both 9 (7) 10 (7)
Age — yr
Mean 58.1±12.6 57.4±14.4
Median (interquartile range) 59 (50–65) 58 (46–69)
Female sex — no. of patients (%) 83 (61) 82 (59)
White race and British nationality — no. of patients (%) 115 (85) 121 (88)
No. of previous cellulitis episodes
Mean 3.7±4.3 3.8±4.8
Median (interquartile range) 2 (1–5) 2 (1–4)
Local warmth, tenderness, or acute pain — no. of patients (%) 136 (100) 138 (100)
Erythema at the affected site — no. of patients (%) 135 (99) 136 (99)
Edema at the affected site — no. of patients (%) 135 (99) 138 (100)
BMI
Mean 35.1±9.4 35.2±9.5
Median (interquartile range) 33.7 (27.7–38.9) 32.5 (27.8–40.7)
Chronic edema — no. of patients (%)†
Asymmetric 64 (47) 64 (46)
Symmetric 28 (21) 28 (20)
Venous insufficiency — no. of patients (%) 36 (26) 34 (25)
Leg ulceration subsequent to cellulitis — no. of patients (%)† 13 (10) 12 (9)
Tinea pedis or toe-web maceration — no. of patients (%) 52 (38) 48 (35)
Surgery >2 wk before the index cellulitis episode — no. of patients (%) 22 (16) 18 (13)
Blunt injury — no. of patients (%) 6 (4) 11 (8)
Definite or possible onychomycosis — no. of patients (%) 30 (22) 39 (28)
Inpatient admission for index episode of cellulitis at baseline —  
no. of patients (%)
65 (48) 59 (43)
Duration of hospital stay for hospitalized participants — days 7.7±5.7 5.7±4.3
* Plus–minus values are means ±SD. No significant between-group differences were observed at baseline. BMI denotes 
body-mass index, calculated as the weight in kilograms divided by the square of the height in meters.
† The values for chronic edema and leg ulceration at baseline vary slightly from the values for the stratification variables 
(preexisting leg edema or ulceration associated with cellulitis) as a result of the different data-collection methods used.
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Predictors of Prophylaxis Failure
Univariable and multivariable analyses of data 
from the 12-month prophylaxis period were per-
formed to identify factors that might predict pro-
phylaxis failure. The following factors were sig-
nificantly associated with a poor response to 
treatment: a body-mass index (BMI; the weight in 
kilograms divided by the square of the height in 
meters) of 33 or higher, three or more previous 
episodes of cellulitis, and the presence of edema 
(borderline significance) (Table 3).
Resource Use and Cost
There were no significant between-group differ-
ences in the use of health care services or in 
costs (Table S2 in the Supplementary Appendix). 
The difference in (undiscounted) NHS costs (per-
patient cost in the penicillin group minus cost in 
the placebo group) was £277 (95% CI, −180 to 
783), or approximately $425, and the difference 
in societal costs was £34 (95% CI, −582 to 655), 
or approximately $50.
Of the 281 recurrences during the trial, 58 re-
274 Underwent randomization
533 Patients were assessed for eligibility
259 Were not eligible
68 Did not have recurrent leg cellulitis
24 Had allergy to penicillin
15 Had recent prophylaxis
22 Had penetrating trauma
21 Were deemed to have reasons that made 
participation not in the best interest of the  
patient
42 Were unwilling or unable to provide consent
67 Had other reasons
136 Were assigned to receive penicillin
129 Started treatment
7 Did not start treatment
138 Were assigned to receive placebo
134 Started treatment
4 Did not start treatment
121 Were included in follow-up phase
(13–36 mo)
6 Were withdrawn from study owing
to death
127 Were included in follow-up phase
(13–36 mo)
4 Were withdrawn from study
1 Died
3 Had other reasons
136 Were included in intention-to-treat
analysis
138 Were included in intention-to-treat
analysis
126 Were included in prophylaxis phase
(0–12 mo)
23 Were withdrawn from study medi-
cation but continued in study
6 Had adverse events
4 Had recurrence of cellulitis
13 Had other reasons
10 Were withdrawn from study
2 Died
8 Had other reasons
131 Were included in prophylaxis phase
(0–12 mo)
29 Were withdrawn from study medi-
cation but continued in study
11 Had adverse events
5 Had recurrence of cellulitis
13 Had other reasons
7 Were withdrawn from study
2 Died
5 Had other reasons
Figure 1. Randomization, Prophylaxis Phase, and Follow-up Phase.
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sulted in hospital admission (30 recurrences in the 
penicillin group and 28 in the placebo group). The 
mean length of the hospital stay was 10.0 days 
in the penicillin group and 9.2 days in the pla-
cebo group.
Discussion
These data show that recurrent cellulitis is com-
mon among patients who have previously had 
two or more episodes. In the placebo group, 53% 
of participants had at least one recurrence during 
the 3-year trial. Low-dose prophylactic penicillin 
given for a period of 12 months almost halved 
the risk of recurrence during the intervention pe-
riod, and patients who received prophylaxis had 
significantly fewer recurrent episodes over the 
3-year period than those who received placebo. Al-
though some level of protection appeared to be sus-
tained for several months after the end of prophy-
lactic therapy, this effect was lost by 36 months, 
a finding that suggests that longer-term prophy-
laxis may be required. Exactly how long such pro-
phylaxis should be given is unclear and remains a 
matter of clinical judgment, depending on wheth-
er any predisposing factors, such as broken skin 
or lymphedema, can be adequately treated.
Results of adjusted analyses suggest that pa-
tients with a BMI of 33 or higher, multiple previ-
ous episodes of cellulitis, or lymphedema of the 
leg had a reduced likelihood of a response to 
prophylaxis. Because such patients are most likely 
to receive long-term prophylaxis,8 this finding war-
rants further investigation. The poor treatment 
response in participants with a high BMI may 
mean that a higher dose of penicillin is required 
in these patients. Reducing edema in patients with 
leg lymphedema may also be important.
The methods used in this trial are similar to 
those used in our previous trial, which investi-
gated a shorter duration of treatment (6 months 
of penicillin) in 123 patients with either a first 
episode of cellulitis (79%) or recurrent cellulitis 
(21%). Although in that trial, the reduction in 
the risk of recurrence with low-dose penicillin as 
compared with placebo was not significant (haz-
ard ratio, 0.53; 95% CI, 0.26 to 1.07; P = 0.08), the 
magnitude of the effect was similar. A Cochrane 
Table 2. Hazard Ratios for Confirmed Recurrence of Cellulitis in the Penicillin Group as Compared with the Placebo Group.
Variable Recurrence of Cellulitis
Percentage-Point 
Difference  
(95% CI)
Hazard Ratio
(95% CI) P Value
no. of events/total no.  
of patients (%)*
Primary analysis: prophylaxis phase, year 1
Penicillin 30/136 (22) −15 (−26 to −4) 0.55 (0.35 to 0.86) 0.01
Placebo 51/138 (37)
Secondary analysis: follow-up phase, years 2 
and 3†
Penicillin 26/97 (27) 0 (−14 to 12) 1.08 (0.61 to 1.93) 0.78
Placebo 22/81 (27)
* The proportion of patients with a recurrence of cellulitis was a prespecified secondary end point. Proportions are pre-
sented as percentages, not person-time event rates.
† The secondary analysis for years 2 and 3 was postrandomization. As a result, the groups may not have been balanced 
at the start of this period.
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Figure 2. Proportion of Participants Who Remained Recurrence-free over Time.
The I bars represent 95% confidence intervals.
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systematic review of the prevention of cellulitis 
is currently under way.20
This was a pragmatic trial that was designed 
to reflect normal clinical care. However, regular 
telephone contact between the coordinating cen-
ter and participants may have increased rates of 
adherence to the study medications.
This trial highlights the need for long-term 
follow-up in studies of preventive treatment. 
Slower-than-expected recruitment meant that com-
plete follow-up data were not available for all par-
ticipants, and findings beyond 18 months should 
be interpreted cautiously.
The main cause of cellulitis is group A strep-
tococci, for which resistance to penicillin is not 
an issue at this time.21 However, because micro-
biologic samples were not collected during the 
trial, the effect of prophylaxis on bacterial resis-
tance more generally is not clear. Future studies 
that include collection of microbiologic samples 
would be useful.
In conclusion, this trial provides evidence that 
patients with two or more episodes of leg cel-
lulitis who are given prophylactic penicillin for 
12 months have fewer recurrences than those giv-
en placebo, without any increase in adverse effects. 
Patients with a high BMI, preexisting edema, or 
at least three episodes of previous cellulitis were 
less likely to have a response to prophylaxis than 
other patients. It is unclear how long prophy-
laxis should be continued.
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Table 3. Factors Predictive of Prophylaxis Failure.*
Factor
Odds Ratio  
(95% CI)† P Value
No. of previous cellulitis 
episodes
≥3 3.23 (1.82–5.73) <0.001
<3 1
Edema
Preexisting edema 1.83 (0.97–3.47) 0.06
No evidence of edema 1
BMI
≥33 2.05 (1.16–3.64) 0.01
<33 1
* Failure of prophylaxis was defined as at least one con-
firmed episode of cellulitis during the prophylaxis phase.
† All effects were included in the model; data for two pa-
tients were not included owing to a missing value for 
BMI.
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